“Study of CAD-9303 in Subjects With Schizophrenia”
This study will consist of Single Ascending Dose (SAD) cohorts that will be randomized, double blind, and placebo-controlled to assess the safety, tolerability, and pharmacokinetics of CAD-9303. The first SAD cohort will be in healthy volunteer subjects. The remaining cohorts will be in participants with schizophrenia.
Drug - CAD-9303
Capsules filled with CAD-9303 from 3 mg up to 1000 mg.
Drug - Placebos
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effects on Neurophysiological Biomarkers of CAD-9303 Oral Treatment in Subjects With Schizophrenia and Normal Healthy Volunteers